Literature DB >> 1313827

Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure.

S M Wahl1.   

Abstract

As we continue to explore the biology of TGF-beta in the network of cells and mediators contributing to host defense, the mechanisms controlling whether the pro- or antiinflammatory effects of this peptide prevail will be unraveled. Understanding these basic mechanisms may offer new approaches for identifying agonists and/or antagonists and in which circumstances their use might be appropriate. The striking differences between local and systemic administration of this cytokine reaffirm that the functional consequences of any biologic mediator must be considered in context (9) and, furthermore, suggest avenues of therapeutic application (Table III). In summary, the central role of TGF-beta in normal and aberrant host defense has become indisputable.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313827     DOI: 10.1007/bf00918135

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  154 in total

1.  Transforming growth factor beta downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes.

Authors:  T Musso; I Espinoza-Delgado; K Pulkki; G L Gusella; D L Longo; L Varesio
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds.

Authors:  S E Lynch; R B Colvin; H N Antoniades
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-beta.

Authors:  A W Taylor; N O Ku; R F Mortensen
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

4.  Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta 1.

Authors:  L D Johns; K C Flanders; G E Ranges; S Sriram
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

5.  Transforming growth factor beta and noncytopathic mechanisms of immunodeficiency in human immunodeficiency virus infection.

Authors:  J Kekow; W Wachsman; J A McCutchan; M Cronin; D A Carson; M Lotz
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  Transforming growth factor-beta production by synovial tissues from rheumatoid patients and streptococcal cell wall arthritic rats. Studies on secretion by synovial fibroblast-like cells and immunohistologic localization.

Authors:  R Lafyatis; N L Thompson; E F Remmers; K C Flanders; N S Roche; S J Kim; J P Case; M B Sporn; A B Roberts; R L Wilder
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

7.  Type beta transforming growth factor is a potent inhibitor of murine megakaryocytopoiesis in vitro.

Authors:  T Ishibashi; S L Miller; S A Burstein
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

8.  Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1.

Authors:  B J Nelson; P Ralph; S J Green; C A Nacy
Journal:  J Immunol       Date:  1991-03-15       Impact factor: 5.422

9.  The glioblastoma-derived T cell suppressor factor/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor.

Authors:  C Siepl; S Bodmer; K Frei; H R MacDonald; R De Martin; E Hofer; A Fontana
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

10.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor.

Authors:  D R Edwards; G Murphy; J J Reynolds; S E Whitham; A J Docherty; P Angel; J K Heath
Journal:  EMBO J       Date:  1987-07       Impact factor: 11.598

View more
  83 in total

1.  Dose-dependent changes in influenza virus-infected dendritic cells result in increased allogeneic T-cell proliferation at low, but not high, doses of virus.

Authors:  SangKon Oh; J Michael McCaffery; Maryna C Eichelberger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Profiles of IFN-gamma and its regulatory cytokines (IL-12, IL-18 and IL-10) in peripheral blood mononuclear cells from patients with multidrug-resistant tuberculosis.

Authors:  J-S Lee; C-H Song; C-H Kim; S-J Kong; M-H Shon; H-J Kim; J-K Park; T-H Paik; E-K Jo
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

4.  Salmonella pathogenicity island 2-dependent expression of suppressor of cytokine signaling 3 in macrophages.

Authors:  Kei-Ichi Uchiya; Toshiaki Nikai
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression.

Authors:  J J Letterio; A G Geiser; A B Kulkarni; H Dang; L Kong; T Nakabayashi; C L Mackall; R E Gress; A B Roberts
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

6.  Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair.

Authors:  L I Gold; J J Sung; J W Siebert; M T Longaker
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

7.  Nanolayered siRNA delivery platforms for local silencing of CTGF reduce cutaneous scar contraction in third-degree burns.

Authors:  Steven A Castleberry; Alexander Golberg; Malak Abu Sharkh; Saiqa Khan; Benjamin D Almquist; William G Austen; Martin L Yarmush; Paula T Hammond
Journal:  Biomaterials       Date:  2016-04-14       Impact factor: 12.479

8.  Effects of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) on neutrophil elastase release.

Authors:  U Bank; D Reinhold; D Kunz; H U Schulz; C Schneemilch; W Brandt; S Ansorge
Journal:  Inflammation       Date:  1995-02       Impact factor: 4.092

9.  Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice.

Authors:  K L Hines; A B Kulkarni; J B McCarthy; H Tian; J M Ward; M Christ; N L McCartney-Francis; L T Furcht; S Karlsson; S M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

10.  Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines.

Authors:  D W McGee; C O Elson; J R McGhee
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.